Decibel Therapeutics
United States
50 articles with Decibel Therapeutics
-
Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of DirectorsDistinguished biopharma executive brings over 20 years of leadership in life sciences
6/2/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of William (Bill) H. Carson, M.D., as Chairman of the Board of Directors.
-
Decibel Therapeutics Expands World-Class Scientific Advisory BoardAdds leaders with expertise in hearing loss and balance disorders, combined with experience in gene therapy development
5/24/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of leading experts in gene therapy, cochlear development and molecular genetics to its Scientific Advisory Board (SAB).
-
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
5/19/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 7:00 am ET.
-
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
5/13/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
-
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting
4/28/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present two digital presentations at the American Society of Gene and Cell Therapy (ASGCT) 24 th Annual Meeting, to be held virtually May 11-14, 2021.
-
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
4/8/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 pm ET.
-
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
3/29/2021
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement for otoferlin dual-vector gene therapy with Catalent- -Launched Amplify™ genetic testing program with Invitae for congenital hearing loss-
-
Decibel Therapeutics Added to Russell 2000 Index
3/22/2021
Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the Russell 2000® Index, as part of the index’s quarterly initial public offering (“IPO”) additions.
-
Decibel Therapeutics to Present at the Barclays Global Healthcare Conference
3/4/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Barclays Global Healthcare Conference
-
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
2/24/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data supporting the company’s gene therapy product candidate, DB-OTO, a potential transformative treatment for individuals with hearing loss due to mutation of the otoferlin gene. T
-
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
2/19/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO)
-
Decibel Therapeutics Announces Pricing of Initial Public Offering
2/12/2021
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of 7,062,000 shares of its common stock at a price to the public of $18.00 per share.
-
Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program
1/29/2021
Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a partnership with Invitae, a leading medical genetics company, to launch Amplify TM , a no-charge genetic testing program
-
Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug Administration
12/17/2020
Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss, a serious and debi
-
Decibel Therapeutics Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance
11/9/2020
Proceeds support advancement of lead gene therapy programs and accelerate development of therapeutics to restore functional hair cells in the inner ear
-
Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology
11/2/2020
Decibel Therapeutics , a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with profound, congenital hearing loss c
-
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
-
Decibel Therapeutics to Present at Citi's 15th Annual BioPharma Virtual Conference
9/2/2020
Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that Laurence Reid Ph.D., Chief Executive Officer of Decibel, will present at Citi's 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 1:10pm ET. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology co
-
Decibel Therapeutics to Present at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
5/11/2020
Decibel Therapeutics to Present at the 23 rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss Associated with Cisplatin Chemotherapy
3/26/2020
Decibel Therapeutics , today announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs . DB-020 is being developed for the prevention of cisplatin-induced hearing loss. The